Diagnostics Archives

News and Trends 26 Apr 2016

Illumina is Suing over NGS Prenatal Screening… Again

Genoma is being sued by Illumina over four patents covering technology for prenatal testing, that uses NGS to diagnose fetal defects. After suing Oxford Nanopore over porin technology, Illumina is back to another contentious field – their patents for a type of non-invasive prenatal testing (NIPT). Illumina has filed a patent infringement suit in the Federal […]

April 26, 2016 - 2 minutesmins - By Denise Neves Gameiro

kiweno bianca gfrei lecture food intolerance diagnostic

News and Trends 25 Apr 2016

The DIY Allergy Blood Test inspiring Austria’s startup Scene

I got to hear the interesting story and business model of kiweno, a digital health startup and rising star in Austria. What’s the product, where is the demand and were there challenges with perceptions after the Theranos scandal? Berlin has a lot of exciting events to feed the thriving startup scene here. And really at […]

April 25, 2016 - 6 minutesmins - By Denise Neves Gameiro

labiotech thomas taapken epicolon biotech epigenomics cancer philipp hemme berlin

News and Trends 14 Apr 2016

We met the Biotech with the First & Only US Approved Blood Test for Colorectal Cancer

Colorectal cancer is the second biggest cancer killer in the US, but Epigenomics could dramatically improve this sad figure. A problem Berlin-based Epigenomics want to solve and just got a significant milestone: an FDA approval for commercialisation. I met with Thomas Taapken, the CEO of the company, in his office in Berlin, a nice historical building with 4 meters ceiling […]

April 14, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 30 Mar 2016

German Biotech targets China for Lung Cancer Liquid Biopsies

Epigenomics (Germany and US) has closed a deal to develop and commercialize a new blood-based lung cancer diagnostic in China, one of its highest performing markets. There are many biotech efforts to find treatments for cancer, but a separate strategy to lower cancer mortality is to improve diagnosis – so that people can be treated when […]

March 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 21 Mar 2016

This CEO was responsible for the Only German Biotech IPO in 2015…

Whilst at the Sachs conference last week, I had the chance to meet with Oliver Schacht, the CEO of Curetis. It’s the only German Biotech which went public last year and this was a good enough reason to have a chat (the company is also really interesting, obviously). Curetis is based in Stuttgart in the […]

March 21, 2016 - 1 minutemin - By Philip Hemme

News and Trends 19 Feb 2016

Biotech of the week: NZYTech, one of the biggest Portuguese Biotech companies

This week, we leave the cold of Norway and head South-West to warmer climates. Not Spain this time, we arrive in the capital of Portugal, Lisbon. This city has a nightlife that can rival Madrid, Castles looking onto beaches and is the location of our biotech of the week, NZYTech. City: Lisbon, Portugal Founded: 2008 Employees: 50 […]

February 19, 2016 - 1 minutemin - By Philip Hemme

News and Trends 14 Aug 2015

Roche’s €382M Acquisition to Expand its Fight against Drug-Resistant Bacteria

The biggest biotech company worldwide has just become even bigger: Roche acquired the Californian GeneWEAVE BioSciences, a privately held company that developed a cool technology to diagnose drug-resistant bacteria. For the integration, Roche shells out $190M (€171M) upfront and up to $235M (€211M) product-related milestones. GeneWEAVE is an American company that developed a technology which is […]

August 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 15 Jul 2015

Personalized Cancer medicines are becoming reality thanks to AstraZeneca and Qiagen’s newly approved combo

A new success for personalized medicines against cancer! AstraZeneca and Qiagen’s collaboration has achieved a major milestone after receiving the FDA’s approval of Iressa, a first-line treatment for a common form of lung cancer. The drug candidate is paired with Qiagen’s therascreen EGRF test as a companion diagnostic test. There is no doubt: the future […]

July 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Jun 2015

Kurma Partners announces the launch of its third fund Kurma Diagnostics

Kurma Diagnostics (KDx), the first Venture Capital fund dedicated to financing early-stage European innovative Diagnostic projects and companies, is here to stay. The firm Kurma Partners, author of this initiative, has received the support from several European and French institutions. The fund has raised €33 Million in its first fundraising round. KDx is a venture […]

June 9, 2015 - 2 minutesmins - By Nicolas Sainte-Foie

News and Trends 3 Apr 2015

The Strategic Focus of Roche-Genentech on Personal Genetic data

Personal Genetic data plays more and more a critical role in drug development. Major Pharma company Roche and its Biotech subsidiary Genentech are iconic in this trend. They have always been the first ones to catch up the wave and get profit from it. Today, Genentech believes and focus on genome sequencing to continue bringing breakthrough […]

April 3, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 27 Nov 2014

Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

Curetis AG, a developer of next-level molecular diagnostic solutions, has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013. Curetis is a young, dynamic and creative molecular diagnostics company. They are specialized in the diagnosis of severe infectious diseases in hospitalized patients. The company helps to combat […]

November 27, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 16 Oct 2014

A Smart Collaboration to Diagnostic and Fight Cancer

New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris. Under this agreement, New Oncology (Cologne-based German Biotech company) will perform comprehensive parallel multigene testing to identify therapeutically relevant alterations in cancer-related genes. New Oncology will apply its proprietary diagnostic platform ‘NEO’, which allows rapid sample processing compatible with both […]

October 16, 2014 - 3 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us